Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: A population-based nationwide cohort study

HIV Medicine

Volumn 11, Issue 2, 2010, Pages 130-136

  Obel, N ^a   Farkas, D K ^b   Kronborg, G ^c   Larsen, C S ^b   Pedersen, G ^d   Riis, A ^b   Pedersen, C ^d   Gerstoft, J ^a   Sorensen H T ^b,e  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e BOSTON UNIVERSITY   (United States)

Author keywords

Highly active antiretroviral therapy; HIV; Ischemic heart disease; Myocardial infarction; Nucleotide analogues

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DENMARK; DRUG EXPOSURE; DRUG USE; FEMALE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; DENMARK; DIDEOXYNUCLEOSIDES; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

EID: 73549088748     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00751.x     Document Type: Article

References (27)

1. Lohse N, Hansen AB, Pedersen G. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
2. Obel N, Thomsen HF, Kronborg G. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007, 44:1625-1631.
3. Friis-Moller N, Weber R, Reiss P. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD Study. AIDS 2003, 17:1179-1193.
4. Friis-Moller N, Sabin CA, Weber R. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.
5. Friis-Moller N, Reiss P, Sabin CA. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735.
6. Sabin CA, Worm SW, Weber R. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD Study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426.
7. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22:F17-F24. DAD Study Group.
8. Lohse N, Hansen AB, Jensen-Fangel S. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005, 37:338-343.
9. Obel N, Engsig F, Rasmussen LD. Cohort profile: The Danish HIV Cohort Study. Int J Epidemiol 2008, doi
10. Frank L. Epidemiology. When an entire country is a cohort. Science 2000, 287:2398-2399.
11. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46:263-268.
12. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98:253-259.
13. Abildstrom SZ, Rasmussen S, Madsen M. Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed. Eur Heart J 2005, 26:990-995.
14. Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med 2007, 356:1705-1707.
15. Bernasconi E, Boubaker K, Junghans C. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002, 31:50-55.
16. Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005, 40:1837-1845.
17. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003, 33:22-28.
18. Moyle GJ, Sabin CA, Cartledge J. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043-2050.
19. Podzamczer D, Ferrer E, Sanchez P. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007, 44:139-147.
20. John M, McKinnon EJ, James IR. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003, 33:29-33.
21. Carr A, Workman C, Smith DE. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002, 288:207-215.
22. Berenguer J, Perez-Elias MJ, Bellon JM. Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naïve HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr 2006, 41:154-159.
23. Petri H, Urguhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991, 10:577-581.
24. Cutrell A, Brothers C, Yeo J, Hernandez J, Lapierre D. Abacavir and the potential risk of myocardial infarction. Lancet 2008, 371:1413.
25. Sabin CA, d'Arminio Monforte A, Friis-Moller N. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008, 46:1101-1110.
26. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007, 7:324-330.
27. Zethelius B, Berglund L, Sundstrom J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.